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Abstract: In 2010, the requirement for human immunodeficiency virus (HIV) testing of 
adult refugees prior to US resettlement was removed, thus leading to a potential for missed 
diagnosis. We reviewed refugee health assessment data and medical charts to evaluate the 
health status of HIV-infected refugees who arrived in Minnesota during 2000–2007, prior 
to this 2010 policy change. Among 19,292 resettled adults, 174 were HIV-infected; 169 
(97%) were African (median age 26.4 (range: 17–76) years). Charts were abstracted for 
157 (124 (79%) with ≥1 year of follow-up). At initial presentation, two of 74 (3%) women 
were pregnant; 27% became pregnant during follow-up. HIV clinical stage varied (59%, 
asymptomatic; 11%, mild symptoms; 10%, advanced symptoms; 3%, severe symptoms; 
17%, unknown); coinfections were common (51 tuberculosis, 13 hepatitis B, 13 parasites, 
four syphilis). Prior to arrival 4% had received antiretrovirals. Opportunistic infections 
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were diagnosed among 13%; 2% died from AIDS-related causes. Arrival screening may be 
needed to identify these HIV-infected refugees and prevent HIV-related morbidity  
and mortality. 




The US Refugee Resettlement Program actively resettles 34,000–119,000 refugees annually [1,2]. 
Refugees face challenges to their physical and mental health. Before migration, refugees undergo 
medical screening for diseases of public health concern. Certain conditions are considered excludible 
by US law. These conditions, when identified, must either be treated successfully or the refugee must 
apply for a waiver that allows immigration despite the condition (US State Department Class A 
waiver). Upon arrival in the United States, all refugees are encouraged to have a domestic health 
screening assessment [3]. Medical screening includes obtaining a general medical history and physical 
examination, screening for infections (e.g., intestinal parasites and hepatitis B), and provision of 
preventive services (e.g., vaccinations) and counseling [3]. Each state is notified of newly arriving 
refugees and facilitates medical follow-up, with particular attention paid to refugees who arrive with 
Class A conditions. In Minnesota, surveillance data from the initial refugee medical screening are 
collected by the Minnesota Department of Health (MDH). These data are evaluated and used to guide 
public health prevention and control activities [4]. 
During 1993–2009, human immunodeficiency virus (HIV) infection was listed as a communicable 
disease of public health importance and an excludible condition for entry to the United States [5]. 
Refugees were allowed to migrate to the United States despite the HIV infection for humanitarian 
reasons after obtaining a Class A waiver. The Class A waiver notification system alerted states and 
health care providers to underlying medical conditions for refugees [5]. During 2000–2009, Minnesota 
was among states that participated in the resettlement waiver program for refugees with HIV infection. 
On 2 November 2009, the Department of Health and Human Services (DHHS) and Centers for Disease 
Control and Prevention (CDC) published a final rule that removed HIV infection from the list of 
communicable diseases of public health significance [5]. Beginning January 2010, HIV testing was 
removed from the overseas medical examination before arrival in the United States. CDC has issued 
guidance that highly encourages post-arrival medical screening and testing for HIV-infection among 
refugees [6]. 
Epidemiologic and clinical data regarding arriving HIV-infected refugees before the US 
government rule change have been limited [7–9]. As a supplemental surveillance project, 
epidemiologic and clinical data on arrival and during ≥1 year of follow-up care were collected for 
HIV-infected refugees who resettled to Minnesota during 2000–2007. We sought to describe these 
refugees’ stage of HIV infection, the burden of concomitant disease, and the initial clinical course. 
Because the impact of the rule change on the health of refugees arriving in the United States is 
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unknown, these data can provide baseline information for subsequent evaluation of the impact of the 
rule change on refugee health status after US arrival. 
2. Methods 
2.1. Participants 
Eligible participants included adults (aged ≥ 17 years) who arrived with known HIV infection or 
who received an HIV diagnosis after arrival. All refugees were primary arrivals, resettled to Minnesota 
from abroad without living elsewhere in the United States. Multiple methods were used to identify 
HIV-infected refugees to ensure inclusion of all eligible participants. Refugees were identified through 
the MDH refugee database screening for any refugee with Class A conditions reported through the US 
Department of State. Refugees identified with HIV infection during the post-arrival refugee screening 
were reported to MDH. Refugees who arrived in Minnesota but did not receive new arrival medical 
screening were identified through MDH HIV surveillance.  
2.2. Data Collection 
In Minnesota, an initial refugee health assessment is recommended within 90 days of arrival. MDH 
recommends that providers review general health history, perform a physical examination, evaluate 
immunization status and provide vaccinations as needed, and perform screening for prevalent 
conditions encountered (e.g., tuberculosis (TB), hepatitis B, intestinal parasites by stool examination, 
lead poisoning for children under 6 years of age, malaria, dental, vision, hearing, and mental health). 
We included health data on new arrivals that were directly reported to the state of Minnesota. By using 
a data collection tool, additional data were abstracted from the follow-up HIV referral clinic that 
provided ongoing care to the refugee. We included demographic information, the stage of HIV infection, 
comorbidities, antiretroviral treatment before and after arrival, and clinical course after arrival.  
2.3. Measures 
Medical chart abstractors categorized the patient into a World Health Organization (WHO) clinical 
stage [10] on the basis of their health condition documented in medical records at their first clinical 
visit after arrival (stage I, asymptomatic; stage II, mild disease; stage III, advanced disease; or stage 
IV, severe disease). Since 1991 and during the arrival of HIV-infected refugees described here, Class 
B1 TB was defined as an abnormal chest radiograph, indicating inactive TB with negative sputum 
smears or suspicion of extrapulmonary TB. In 2007, Class B1 TB was merged with Class B2 to 
include TB that is not clinically active and not infectious; old, healed TB and previously treated TB are 
also included.  
2.4. Analysis 
The analyses are primarily descriptive. We examined demographic information and described  
co-morbidities such as the proportions with TB, hepatitis B infection, parasitic infections, and sexually 
transmitted infections noted on the domestic refugee health assessment. In addition, longitudinal data 
after arrival was examined for outcome data such as successful integration into ongoing care, and 
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ongoing or new morbidity and mortality due to HIV infection. We also compared the types and 
prevalence of coinfections among newly arrived refugees who were HIV-infected versus  
HIV-uninfected arriving during the same period. For this comparison, if a refugee tested positive for 
HIV during the overseas exam but was re-tested and found to be negative in the States, they were 
categorized as HIV-uninfected; conversely, if a refugee tested negative for HIV overseas but was  
re-tested and found to be positive in the US, they were included as HIV-infected.  
We used Χ2-test or Fisher’s exact test when expected values were ≤ 5. Data were managed with 
Microsoft® Access® (Microsoft Corporation, Redmond, WA, USA). Statistical analyses were 
conducted by using SAS® Version 9.1 (SAS Institute, Inc., Cary, NC, USA) and Stata® 10 (StataCorp 
LP, College Station, TX, USA). 
2.5. Ethics 
Each participating institution that provided care or data considered this chart review and analysis to 
be a supplementary public health surveillance activity and determined it not to be human subjects 
research; therefore, approval by an institutional review board and informed consent were not required. 
3. Results 
During 1 January 2000–31 December 2007, a total of 31,141 refugees were resettled to Minnesota, 
among whom 19,292 were adults aged ≥17 years, and 17,013 completed the initial refugee health 
assessment. There were 174 adult refugees identified as having HIV. One hundred fifty-seven (85%) 
had medical charts reviewed and were eligible for inclusion (Figure 1, Table 1). This included two 
adult refugees with an HIV waiver who missed their refugee health screening, but received follow-up 
HIV care. 
Characteristics of the HIV-infected refugees identified through health screening and those with or 
without medical charts are described in Table 1. Among the 157 persons with medical charts reviewed, 
83 (53%) indicated they were married or had a partner (49 had a partner with unknown HIV status). 
Among the 83 who had medical charts noting that they had a partner, 41 (49%) had a partner in the 
United States; 30 (36%) did not have their partner in the United States, and 12 (14%) had unknown 
partner location status. Of the 41 who reported having a partner in the United States, 11 (27%) had it 
noted in their medical chart that their partner was also HIV-infected; 20 (49%) had partners who were 
reportedly uninfected; and 10 (24%) had reported no information on partner’s HIV status. Overall,  
80 (51%) reported having children, and 30 (19%) had no children; 47 (30%) had no information 
regarding children. Among the 80 refugees with children, three (4%) had medical charts that noted 
having children with HIV infection; 37 (46%) had children without HIV infection; and 40 (50%) had 
no record of children’s HIV-status. Among 74 female refugees, two (3%) were pregnant on initial 
presentation; 20 (27%) became pregnant sometime after their initial presentation to a health clinic. 
After arrival, the median time to pregnancy for 16 females with both pregnancy and arrival dates 
documented was 2.2 years (range, 0.1–7.5 years). 
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Figure 1. Refugees Entering Minnesota During 2000–2007 Who Had HIV Waivers or 
Were Diagnosed During Refugee Screening Identified as HIV-Infected Upon Further 
Testing and with Medical Charts Available for Review.  
 
Table 1. Demographic Characteristics of 184 Refugees Diagnosed with HIV Infection, and 























No. (%) No. (%) No. (%) No. (%) No. (%) 
Total 184 (100) 25 (100) 174 (100) 165 (100) 157 (100) 
Male 96 (52) 13 (52) 96 (55) 92 (56) 83 (53) 
Female 88 (48) 12 (48) 78 (45) 73 (44) 74 (47) 
Age (years)      
<5 1 (1) 1 (4) 0 (0) 0 (0) 0 (0) 
5–14 3 (2) 3 (12) 0 (0) 0 (0) 0 (0) 
15–24 79 (43) 14 (56) 75 (43) 70 (42) 65 (41) 
25–44 61 (33) 4 (16) 61 (35) 58 (35) 56 (36) 
45–64 36 (20) 2 (8) 34 (20) 33 (20) 33 (21) 
≥65 4 (2) 1 (4) 4 (2) 4 (2) 3 (2) 
Region of origin      
Sub-Saharan Africa 178 (97) 22 (88) 169 (97) 161 (98) 154 (98) 
South, Southeast Asia 6 (3) 3 (12) 5 (3) 4 (2) 3 (2) 
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No. (%) No. (%) No. (%) No. (%) No. (%) 
Year of arrival      
2000 27 (15) 6 (24) 24 (14) 24 (15) 21 (13) 
2001 19 (10) 0 (0) 19 (11) 19 (12) 19 (12) 
2002 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
2003 20 (11) 0 (0) 20 (11) 18 (11) 19 (12) 
2004 48 (26) 5 (20) 46 (26) 45 (27) 43 (27) 
2005 26 (14) 5 (20) 24 (14) 23 (14) 21 (13) 
2006 33 (18) 8 (32) 30 (17) 26 (16) 24 (15) 
2007 11 (6) 1 (4) 11 (6) 10 (6) 10 (6) 
* Excludes two refugees who arrived w/ HIV waiver but tested negative in the US.  
3.1. HIV/AIDS Treatment and Clinical Status  
Among the 157 HIV-infected refugees who had medical charts available for review, 131 (83%) had 
sufficient clinical information to categorize the patient by WHO clinical stages as described 
previously. Among these, 108 (82%) had CD4+ count information available for ≤1 year after their 
initial clinical visit (Table 2). The WHO stages at first provider visit were Stage I (asymptomatic, 
59%), Stage II (mild, 11%), Stage III (advanced, 10%), and Stage IV (severe, 3%); 26 of the  
157 (17%) had unknown or unrecorded CD4+counts on their medical charts. The median CD4+ count 
of those who were asymptomatic, mildly symptomatic, or had severe symptoms increased during the  
1-year follow-up periods, although the range of CD4+ counts varied widely. Before arrival, 6 (4%) 
reported having received or were receiving standard antiretroviral therapy (ART). After arrival,  
109 (69%) received ART.  
Table 2. Estimated World Health Organization Clinical Stage of HIV/AIDS and Initial 
CD4+ Counts for HIV-Infected Refugees at First Provider Visit After and Subsequent 
CD4+ Counts.  
  Initial  
CD4+ Count 
1st Month  
CD4+ Count 
6th Month  
CD4+ Count 
















Asymptomatic  93 (59) 91 300 (32–1,084) 79 320 (80–1,032) 77 339 (50–1,146) 74 352 (65–1,291) 
Mild symptoms  18 (11) 18 181 (15–440) 17 203 (47–375) 16 267 (52–517) 15 287 (129–547) 
Advanced 
symptoms 
 16 (10) 16 271 (7–452) 16 233 (7–590) 15 251 (64–581) 15 382 (47–503) 
Severe symptoms  4 (3) 3 10 (3–66) 4 80 (5–140) 4 114 (69–156) 4 138 (110–192) 
Unknown  26 (17) 17 283 (76–1,921) 11 340 (97–665) 12 319 (153–636) 11 321 (215–770) 
Total 157 (100) 145  127  124  119  
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3.2. Infections and Opportunistic Infections 
Twenty-one HIV-infected refugees (13%) received diagnoses with ≥1 opportunistic infection (OI), 
which included candidiasis (n = 9), pulmonary (n = 6) and disseminated TB (n = 2), Mycobacterium 
avium complex (n = 7), Pneumocystis jiroveci (n = 3), Kaposi’s sarcoma (n = 2), toxoplasmosis (n = 1), 
cryptosporidiosis (n = 1), and histoplasmosis (n = 1). Among the 21 refugees who experienced an OI, 
1 did so before arrival; eight were reported to have an OI 1–3 months after their arrival; and  
13 experienced an OI 4 months–7 years after their arrival in the United States. Three (2%) died, all 
from AIDS-related causes, between 3–4 years after arrival into the United States; none were reported 
to have received ART before arrival and two were reported to have received ART after arrival. 
During 2000–2007, there were 161 HIV-infected refugees and 12,287 HIV-uninfected refugees who 
arrived in Minnesota from sub-Saharan African countries and received an initial refugee health 
assessment (Table 3). This included four refugees who tested positive for HIV overseas but were found 
to be HIV-uninfected upon re-testing in the US, and one refugee found to be HIV-infected in the US at 
health screening assessment. Coinfections for HIV-infected refugees as well as those same infections 
for HIV-uninfected refugees were common at initial health screening visits for refugees resettled from 
sub-Saharan Africa (Table 3). TB disease was more common among HIV-infected refugees, compared 
with HIV-uninfected refugees. The proportion of HIV-infected refugees with hepatitis B infection was 
similar to HIV-uninfected refugees. Parasitic infections were slightly less common among HIV-
infected refugees, compared with HIV-uninfected refugees. Syphilis was more frequently observed 
among HIV-infected refugees, compared with HIV-uninfected refugees, and none of the HIV-infected 
refugees included were coinfected with chlamydia or gonorrhea. 
Table 3. Demographics and Coinfections Identified during Routine Refugee Health 
Screening Assessment Comparing HIV-Infected to HIV-Uninfected Refugees from  
Sub-Saharan Africa Resettled to Minnesota during 2000–2007.  
Characteristic 
HIV-Infected Refugees 
(n = 161) 
HIV-Uninfected 
Refugees (n = 12,287) P Value * 
No. (%) No. (%) 
Sex  
0.300 *  Male 89 (55.3) 6,297 (51.2) 
 Female 72 (44.7) 6,009 (48.8) 
Age (years)  
<0.001 * 
 17–24 75 (46.6) 7,273 (59.1) 
 25–44 51 (31.7) 2,091 (17.0) 
 45–64 31 (19.3) 2,268 (18.4) 
 ≥65 4 (2.5) 674 (5.5) 
Year of arrival  
0.004 * 
 2000 24 (14.9) 1,557 (12.7) 
 2001 19 (11.8) 1,135 (9.2) 
 2002 0 (0) 257 (2.1) 
 2003 18 (11.2) 1,239 (10.1) 
 2004 45 (28.0) 2,190 (17.8) 
 2005 19 (11.8) 1,994 (16.2) 
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Table 3. Cont. 
Characteristic 
HIV-Infected Refugees 
(n = 161) 
HIV-Uninfected 
Refugees (n = 12,287) P Value * 
No. (%) No. (%) 
Year of arrival  
 2006 26 (16.2) 2,684 (21.8) 
 2007  10 (6.2) 1,250 (10.2) 
Time to arrival screening  
<0.001 * 
 ≤29 days 140 (87.0) 5,024 (40.8) 
 30–59 days 19 (11.8) 4,626 (37.6) 
 60–90 days 1 (0.6) 1,951 (15.9) 
 ≥91 days 1 (0.6) 705 (5.7) 
Tuberculosis  
<0.001 
Disease 5 (3.1) 206 (1.7) 
Latent infection 55 (34.2) 6,978 (56.8) 
No tuberculosis 91 (56.5) 4,280 (34.8) 
 Not tested 10 (6.2) 823 (6.7) 
Hepatitis B  
0.809 * 
Positive test hepatitis B 16 (9.9) 1,177 (9.6) 
Negative test hepatitis B 143 (88.8) 10,845 (88.3) 
Not tested 2 (1.2) 265 (2.2) 
Parasitic infections  
0.041 * 
Any parasitic infections § 12 (7.5) 1,501 (12.2) 
No parasitic infections 146 (90.7) 10,041 (81.6) 
Not tested 3 (1.9) 764 (6.2) 
Schistosomiasis 5 (3.1) 175 (1.4) 0.192 †
Giardiasis 4 (2.5) 368 (3.0) 0.822 †
Amebiasis 2 (1.2) 250 (2.0) 0.589 †
Strongyloidiasis 1 (0.6) 26 (0.2) 0.324 †
Taenia species infection 0 (0) 10 (<0.1) >0.999 †
 Other 0 (0) 954 ** (7.8) <0.001 †
Sexually transmitted infections  
Syphilis 6 (3.7) 162 †† (1.3) 0.018
No syphilis 117 (72.7) 9,600 (78.0) 
Not tested 38 (23.6) 2,544 (20.7) >0.999
  
Gonorrhea 0 (0) 4 §§ (<0.1) 
No gonorrhea 18 (11.2) 1,080 (8.8) 
Not tested 143 (88.8) 11,222 (91.2) >0.999
  
Chlamydia 0 (0) 3 (0.02 ) 
No chlamydia 24 (14.9) 1,112 (9.0) 
Not tested 137 (85.1) 11,191 (90.9) 
* Χ2 test used; all others Fisher’s exact test. § A person might have been coinfected with ≥2 types of 
parasites. ** 505 Blastocystis hominis, 407 Trichuris trichiura, 119 Dientamoeba, 30 Hookworm species, 25 
Ascaris lumbricoides, two Helicobacter pylori, one Cryptosporidium, 12 other. † Compared to no parasitic 
infection. †† one coinfected with gonorrhea/chlamydia/syphilis. §§ one coinfected with gonorrhea/chlamydia. 
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Figure 2. Tuberculosis (TB) Diagnosis and Treatment Status Among HIV-Infected Refugees Resettled to Minnesota, 2000–2007.  
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Among the 157 refugees with charts reviewed, 51 (32%) were diagnosed with TB disease or LTBI 
at their domestic health assessment with an additional eight (5%) refugees developing TB disease after 
arrival. Nineteen (12%) had a record of Class B1 TB status before US arrival (Figure 2). Two of 19 
(11%) HIV-infected refugees with a history of TB also had TB disease diagnosed at domestic health 
assessment; both completed treatment. Four Class B1 arrivals (21%) were diagnosed with LTBI; all 
four initiated treatment and three (75%) completed treatment. Among HIV-infected refugees with no 
TB Class upon arrival three (2%) of 138 were diagnosed with active TB disease at their domestic 
health assessment; all three completed treatment.  
Among 42 HIV-infected refugees with no TB class who were diagnosed with LTBI at domestic 
health assessment, 34 (81%) initiated treatment and 19 (56%) of those completed treatment. Of those 
who did not complete treatment, eleven (26%) were non-adherent to prescribed treatment, four (10%) 
were lost to follow-up, and eight (19%) did not have a treatment start-date recorded. Reasons for lack 
of start-date were loss to follow-up (38%), treatment was determined to not be indicated by the 
provider (13%), or no reason was recorded (63%).  
4. Discussion and Conclusions 
In Minnesota, during the period prior to the cessation of the waiver requirement, HIV-infected 
refugees arrived in Minnesota at varying stages from asymptomatic infection to advanced disease.  
A majority had no prior record of ART; coinfections detected at post-arrival domestic health screening 
were common; and three AIDS-related deaths occurred. Two HIV-infected refugee women were 
pregnant at arrival, and 20 became pregnant after arrival, thus requiring specialized care to prevent 
mother-to-child HIV transmission. These findings reinforce the importance of providing information 
regarding HIV-infection to refugee populations [8]. In addition, these data may serve as useful baseline 
comparison for the evaluation of changing practices and guidelines of HIV-testing.  
Before 2010, documentation of HIV infection through the waiver program was the primary means 
of identifying HIV-infected refugees prior to arrival. The impact of the 2009 rule change on refugee 
health, particularly those who are HIV-positive, is unknown. Because early identification and 
appropriate initiation of therapy for HIV is associated with decreased morbidity and improved overall 
survival [11], collaboration between refugee health programs and HIV counseling and testing services 
will be of increased importance. Current CDC guidelines recommend HIV screening in health-care 
settings for all persons aged 13–64 years, including refugees [3]. Voluntary screening is encouraged by 
CDC for all refugees on arrival, when counseling and referrals for care, treatment, and preventive 
services are available [6]. These changes are in accordance with the United Nations High 
Commissioner for Refugees (UNHCR), WHO, and United Nations Program on HIV/AIDS 
recommendations regarding HIV testing and counseling in health facilities for refugees, internally 
displaced persons, and other persons of concern to UNCHR [12].  
Identifying health needs and providing care to resettled refugees fits within the framework of 
upholding health as a human right. Data regarding HIV prevalence and risks for acquiring HIV 
infection among refugee populations are sparse [13,14], and testing might not be available before 
arrival. After the change from required HIV testing, timely and accurate HIV diagnosis and treatment 
is of increased importance. Therefore, the arrival refugee medical examination provides an optimal 
opportunity to identify HIV infection among refugees and provide treatment. Coinfections are 
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common and morbidity likely can be reduced with earlier diagnosis and treatment of HIV infection. As 
illustrated by the frequency of pregnancy among this population, the early identification of HIV after 
arrival can also reduce the likelihood of perinatal HIV transmission. Continued collaboration between 
public health agencies and health care providers will be necessary to follow and assess refugees’ health 
status, including HIV infection, in Minnesota and throughout the United States. 
Similar to other reports investigating the health of HIV-infected refugees, coinfections were 
commonly detected [7,15,16]. The high prevalence of TB among refugees described in this analysis is 
expected, considering that TB is a common coinfection among HIV-infected persons and in  
sub-Saharan Africa [17,18]. Knowing a patient’s HIV status may influence clinicians suspicion and 
approach to TB infection and disease diagnosis. Moving forward, with the rule change, clinicians will 
not have the advantage of knowing the HIV status prior to arrival, making post-arrival screening 
important in detecting both HIV and TB disease. 
During the period covered by chart reviews, US immigrant and refugee TB screening requirements 
were updated from 1991 requirements. In 1991, the requirements included a chest radiograph and three 
sputum samples (acid-fast–bacilli stain only) for disease detection. In 2007, these technical instructions 
were updated to require screening to include mycobacterial culture and completion of directly 
observed therapy before US arrival for anyone with TB disease [19]. These data indicate that a 
substantial proportion (52%) of those with LTBI detected during their domestic health assessment did 
not complete treatment or treatment outcome was missing; LTBI patients do not have access to 
directly observed therapy making it challenging for public health and/or health care providers to 
monitor their treatment through completion. Linguistic or socio-cultural barriers and loss to follow-up 
due to out-migration are additional challenges that can disrupt LTBI treatment adherence. LTBI and 
treatment completion are not reportable to the TB surveillance or refugee health programs, which may 
have led to underreporting of treatment outcomes. In recent years, the refugee health program at the 
Minnesota Department of Health has improved its processes to actively track LTBI treatment 
outcomes. For refugees arriving from 2008 to 2010, the program has seen an increase in the proportion 
of refugees who follow LTBI treatment through to completion, due in part to improved tracking and 
reporting; 78% of all refugees who completed LTBI treatment, compared to only 48% during  
2000–2007. However, this is still inadequate, particularly for those with HIV infection where the TB 
reactivation rate is excessive. 
These data, based on medical chart review of resettled refugees, provide a unique summary of the 
health status of HIV-infected refugees during a period when HIV-infection status was known before 
US arrival. However, this study has certain limitations. As a retrospective medical chart review, certain 
clinical details might not be recorded in medical charts; others might have been missed during the 
process of chart abstraction; and patients might have sought health care elsewhere from the site of 
medical chart abstraction. To maintain a simplified data collection tool, certain details (e.g., the date 
that ART was prescribed) and treatment rationale were not ascertained. This review did not include 
psychosocial components, as others have included [16]. Despite these limitations, our findings provide 
additional information given the limited data that exist regarding HIV-infection among refugee 
populations and can serve as useful baseline comparisons in lieu of changing practices and guidelines 
of HIV-testing and availability of ART. To complement medical chart abstractions, future evaluations of 
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health status of HIV-infected refugee populations should include culturally appropriate patient interviews 
to better understand their knowledge, attitudes, and beliefs regarding HIV/AIDS testing and care. 
In Minnesota, evaluating the health of all refugees through a health screening assessment, 
regardless of HIV-infection status is a routine MDH activity, provides a means for determining care 
and prevention needs, and includes constant interaction within MDH programs (e.g., TB prevention 
services follow-up). During 2000–2007, the refugee health screening rate was 94.8% of 29,182 eligible 
resettled refugees. Refugees are ineligible if they move out of state or to an unknown location or have 
incorrect contact information. In lieu of the waiver program, routine HIV screening is the most 
efficient way to detect HIV infection and provide appropriate and timely care. 
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